NAD⁺ chemistry and cellular pool
NAD⁺ is a dinucleotide composed of adenosine monophosphate and nicotinamide mononucleotide linked through a phosphoanhydride bond. It exists in two redox forms — the oxidised NAD⁺ and the reduced NADH — and is present intracellularly in the millimolar range across multiple subcellular compartments. Distinct pools in cytoplasm, mitochondria, and nucleus have partially separated regulation.
The NAD⁺ / NADH couple is central to cellular redox biology. It carries electrons from catabolic reactions to the mitochondrial electron transport chain, coupling substrate oxidation to ATP synthesis. This redox role has been recognised since NAD⁺ was first characterised in the early twentieth century.
NAD⁺-consuming enzymes: sirtuins, PARPs, and CD38
Beyond its redox role, NAD⁺ is consumed by a family of signalling enzymes that use it as a substrate — a role recognised more recently. Three enzyme families dominate this signalling consumption: the sirtuins (SIRT1–SIRT7, NAD⁺-dependent deacylases with roles in gene expression, stress response, and mitochondrial biology), the PARPs (poly-ADP-ribose polymerases, primarily responding to DNA damage), and CD38 (a ubiquitous NAD⁺-consuming enzyme with immune and calcium-signalling roles).
Because these enzymes consume NAD⁺ stoichiometrically, their activity depletes the cellular pool. Chronic elevation of DNA-damage or inflammatory signalling — both features of aging — drives sustained NAD⁺ consumption and contributes to the decline in cellular NAD⁺ levels observed across aging tissues.
Biosynthesis: de novo, Preiss-Handler, and salvage pathways
Cellular NAD⁺ pools are maintained through three biosynthetic pathways. The de novo pathway synthesises NAD⁺ from tryptophan through the kynurenine pathway — a minor contributor to bulk cellular NAD⁺ but an active area of research through its connection to inflammation and CNS biology. The Preiss-Handler pathway uses nicotinic acid and is important in specific tissues. The salvage pathway recycles nicotinamide (released as NAD⁺ is consumed) back into NAD⁺ through NMN and NR intermediates and is quantitatively the dominant maintenance pathway in most cells.
The salvage pathway is why nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are the most-studied NAD⁺ precursors in the research literature — they enter the salvage pathway directly and increase NAD⁺ synthesis. Both are commercial research compounds and appear frequently in preclinical longevity and metabolism studies.
NAD⁺ decline in aging
One of the observations that anchors current NAD⁺ research is the reproducible decline in tissue NAD⁺ levels observed with aging across mammalian species. The decline has been characterised in liver, muscle, brain, and other tissues, with reported magnitudes of 50% or more between young and aged animals in some models.
The mechanistic drivers of this decline are proposed to include increased CD38 expression, sustained PARP activation from accumulating DNA damage, and reduced expression of biosynthetic enzymes. The consequences downstream include reduced sirtuin activity — with effects on mitochondrial biogenesis, stress response, and metabolic homeostasis — and reduced capacity to respond to further metabolic stress. This framework connects NAD⁺ biology to the broader aging-biology literature.
Preclinical research directions
Preclinical work on NAD⁺ biology falls into several overlapping directions. Precursor-supplementation studies use NR or NMN to elevate cellular NAD⁺ pools and characterise downstream endpoints — mitochondrial function, insulin sensitivity, endurance capacity, and age-related phenotypes in rodent models. CD38 inhibition studies use small-molecule inhibitors to reduce NAD⁺ consumption and assess whether pool preservation reproduces the effects of precursor supplementation. Sirtuin-modulator studies target specific sirtuin isoforms directly.
Direct administration of NAD⁺ itself, as opposed to its precursors, is less common in the mechanism-focused literature because oral NAD⁺ is not efficiently absorbed intact and injected NAD⁺ has short in-vivo half-life. Precursor-based studies remain the dominant approach in preclinical work characterising NAD⁺-elevating interventions.
Comparative context and integration with mitochondrial peptide research
NAD⁺ biology intersects with the mitochondrial-derived peptide literature (see the MOTS-c article) in the shared axis of AMPK signalling and mitochondrial biogenesis. Both NAD⁺-elevating and mitochondrial-derived-peptide interventions engage overlapping downstream pathways, and preclinical studies characterising combined or comparative effects are an area of active work.
This convergence — small-molecule cofactor biology and small-peptide signalling biology meeting at AMPK / SIRT1 / mitochondrial biogenesis — is one of the more mechanistically satisfying integrations in current longevity research. It is also a reminder that no single molecule or pathway defines the field.
Analytical considerations
Because NAD⁺ is not a peptide, its analytical characterisation uses different methods than the rest of the compounds in this research library. Identity and purity are assessed by HPLC with UV detection (NAD⁺ has a characteristic absorbance at 260 nm) and mass spectrometry (monoisotopic mass approximately 663 Da). Enzymatic assays that measure NAD⁺ turnover through cofactor-dependent reactions can be used for functional characterisation.
For cellular NAD⁺ quantification in preclinical samples, HPLC methods with enzymatic cycling amplification or LC-MS/MS with isotope-labelled internal standards are the reference methods. Immunoassays for NAD⁺ are less common than for peptide analytes.
Worked examples
Storage of NAD⁺ solid material
- 01Store sealed, desiccated, and away from light — NAD⁺ is somewhat light-sensitive.
- 02Refrigerate for short-term storage or freeze at −20 °C or below for extended storage.
- 03Bring to room temperature before opening to limit condensation.
Preparing an aqueous working solution
- 01Reconstitute in appropriate buffer at the desired concentration — pH near neutral for stability.
- 02Verify concentration spectrophotometrically at 260 nm using the published extinction coefficient.
- 03Aliquot and freeze; NAD⁺ in solution is less stable than the solid form, particularly at basic pH.
- 04Avoid repeated freeze-thaw cycles.
Frequently asked questions
Is NAD⁺ a peptide?
No. NAD⁺ is a small-molecule dinucleotide, not a peptide. It is included in this research library because of its central role in the same longevity-biology literature that peptide research often overlaps with, and because NAD⁺ precursors (NR, NMN) appear frequently alongside peptide tool compounds in preclinical protocols.
Why do researchers use NR or NMN rather than NAD⁺ itself?
Oral NAD⁺ is not efficiently absorbed intact, and injected NAD⁺ has a short in-vivo half-life. NR and NMN are precursors that enter the salvage biosynthesis pathway directly, elevating cellular NAD⁺ pools more effectively than administration of NAD⁺ itself.
Which enzymes consume cellular NAD⁺?
The dominant consumers are the sirtuin family (SIRT1–SIRT7, NAD⁺-dependent deacylases), the PARPs (DNA-damage response), and CD38 (immune and calcium signalling). Chronic activation of any of these drives NAD⁺ pool depletion.
Does cellular NAD⁺ really decline with age?
The observation is well-reproduced across multiple mammalian tissues and species, with reported magnitudes of 50% or more between young and aged animals in some rodent models. The mechanistic drivers include increased CD38 expression, sustained PARP activation from DNA damage, and reduced biosynthetic enzyme expression.
How is NAD⁺ characterised analytically?
HPLC with UV detection at 260 nm and mass spectrometry (monoisotopic mass approximately 663 Da) for identity and purity. For cellular NAD⁺ quantification, HPLC with enzymatic cycling amplification or LC-MS/MS with isotope-labelled internal standards are the reference methods.
References
Selected published research referenced in this article.
- 01Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529–547. PubMed
- 02Verdin E. NAD⁺ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208–1213. PubMed
- 03Yoshino J, Baur JA, Imai SI. NAD⁺ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27(3):513–528. PubMed
- 04Bogan KL, Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD⁺ precursor vitamins in human nutrition. Annu Rev Nutr. 2008;28:115–130. PubMed
- 05Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 2016;23(6):1127–1139. PubMed
- 06Cantó C, Menzies KJ, Auwerx J. NAD⁺ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 2015;22(1):31–53. PubMed